OXB is launching what it describes as a fast-track development and manufacturing offering in response to growing customer demand. Specifically, this service will be for clients utilizing lentiviral (LV) and adeno-associated viral (AAV) vectors. For these clients, OXB, a cell and gene therapy-focused CDMO, will provide expedited routes to good manufacturing practice (GMP) manufacture. OXB Proprietary Platforms in Focus The fast-track offering makes use of two proprietary OXB platforms, n...